STATEMENT RE IMMUNOCORE HOLDINGS PLC
Source: RNS
BioPharma Credit PLC
12 November 2024
BIOPHARMA CREDIT PLC
(THE "COMPANY")
STATEMENT RE Immunocore Holdings plc
Pharmakon Advisors, LP, the investment manager of the Company, notes the announcement released 8 November 2024 by Immunocore Holdings plc ("Immunocore") regarding the prepayment in full of the US$50 million senior secured term loan, of which the Company had an investment of US$25 million. The prepayment included a US$1.5 million prepayment fee, of which the Company received US$750,000.
The Company had previously announced on 21 November 2022 an investment in a senior secured loan to Immunocore of up to US$100 million in up to two tranches. The Company had previously funded US$25 million and Immunocore did not draw the second tranche. In connection with this final repayment, the Company received US$1,014,063 of accrued interest and prepayment fees.
Enquiries:
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 509
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
